MedTrace Logo

Phase 1 Single Ascending Dose Study With ATX101

NCT07107802 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-11-28

No results posted yet for this study

Summary

The main objective of this study is to assess the safety and tolerability of intravenously administered ATX101 in healthy adults following single ascending doses of ATX101. The pharmacokinetic profile of ATX101 and its metabolites will also be investigated.

Conditions

  • Healthy Participants

Interventions

DRUG

ATX101

Single intravenous dose

DRUG

Placebo

Single intravenous dose

Sponsors & Collaborators

  • Aurobac Therapeutics SAS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-19
Primary Completion
2025-10-24
Completion
2025-10-24

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07107802 on ClinicalTrials.gov